Volume 73, Issue 3 , Pages 878-885, 1 March 2009
Tissue pO2 of Orthotopic 9L and C6 Gliomas and Tumor-Specific Response to Radiotherapy and Hyperoxygenation
Purpose
Tumor hypoxia is a well-known therapeutic problem; however, a lack of methods for repeated measurements of glioma partial pressure of oxygen (pO2) limits the ability to optimize the therapeutic approaches. We report the effects of 9.3 Gy of radiation and carbogen inhalation on orthotopic 9L and C6 gliomas and on the contralateral brain pO2 in rats using a new and potentially widely useful method, multisite in vivo electron paramagnetic resonance oximetry.
Methods and Materials
Intracerebral 9L and C6 tumors were established in the left hemisphere of syngeneic rats, and electron paramagnetic resonance oximetry was successfully used for repeated tissue pO2 measurements after 9.3 Gy of radiation and during carbogen breathing for 5 consecutive days.
Results
Intracerebral 9L gliomas had a pO2 of 30–32 mm Hg and C6 gliomas were relatively hypoxic, with a pO2 of 12–14 mm Hg (p < 0.05). The tissue pO2 of the contralateral brain was 40–45 mm Hg in rats with either 9L or C6 gliomas. Irradiation resulted in a significant increase in pO2 of the 9L gliomas only. A significant increase in the pO2 of the 9L and C6 gliomas was observed in rats breathing carbogen, but this effect decreased during 5 days of repeated experiments in the 9L gliomas.
Conclusion
These results highlight the tumor-specific effect of radiation (9.3.Gy) on tissue pO2 and the different responses to carbogen inhalation. The ability of electron paramagnetic resonance oximetry to provide direct repeated measurements of tissue pO2 could have a vital role in understanding the dynamics of hypoxia during therapy that could then be optimized by scheduling doses at times of improved tumor oxygenation.
Glioma, Electron paramagnetic resonance oximetry, EPR oximetry, partial pressure of oxygen, pO2, Radiotherapy, Carbogen
To access this article, please choose from the options below
Supported by the National Cancer Institute (Grant CA120919) and National Institutes of Health (Grant PO1EB2180).
Conflict of interest: none.
PII: S0360-3016(08)03663-8
doi:10.1016/j.ijrobp.2008.10.025
© 2009 Elsevier Inc. All rights reserved.
Volume 73, Issue 3 , Pages 878-885, 1 March 2009
